Thermo Fisher Scientific Inc. $TMO Stock Position Lowered by Bank Pictet & Cie Europe AG

Bank Pictet & Cie Europe AG cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 19,787 shares of the medical research company’s stock after selling 3,036 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Thermo Fisher Scientific were worth $13,357,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. 55 North Private Wealth LLC raised its position in Thermo Fisher Scientific by 40.9% during the 3rd quarter. 55 North Private Wealth LLC now owns 906 shares of the medical research company’s stock worth $612,000 after buying an additional 263 shares during the last quarter. Jeppson Wealth Management LLC purchased a new stake in shares of Thermo Fisher Scientific in the third quarter valued at about $213,000. James Hambro & Partners LLP increased its stake in shares of Thermo Fisher Scientific by 0.8% during the third quarter. James Hambro & Partners LLP now owns 231,390 shares of the medical research company’s stock worth $156,260,000 after acquiring an additional 1,919 shares during the period. James T. Borello RIA acquired a new position in Thermo Fisher Scientific during the 3rd quarter worth approximately $57,000. Finally, V Square Quantitative Management LLC increased its position in Thermo Fisher Scientific by 2.2% during the 3rd quarter. V Square Quantitative Management LLC now owns 2,451 shares of the medical research company’s stock worth $1,655,000 after purchasing an additional 53 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on TMO shares. Weiss Ratings raised Thermo Fisher Scientific from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. Barclays boosted their target price on shares of Thermo Fisher Scientific from $650.00 to $750.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Royal Bank Of Canada set a $740.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, October 15th. Guggenheim initiated coverage on shares of Thermo Fisher Scientific in a report on Thursday, October 15th. They issued a “buy” rating for the company. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $720.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday, September 25th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $654.05.

Insider Buying and Selling

In other news, CAO Joseph Holmes sold 420 shares of the company’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the sale, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Shafer sold 25,500 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the sale, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 73,768 shares of company stock valued at $44,122,820. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO stock traded up $7.25 during mid-day trading on Tuesday, reaching $686.63. The stock had a trading volume of 1,648,560 shares, compared to its average volume of 2,252,220. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $704.00. The company has a market cap of $253.88 billion, a P/E ratio of 36.95, a price-to-earnings-growth ratio of 2.89 and a beta of 0.87. The business has a 50-day simple moving average of $638.93 and a 200 day simple moving average of $549.90. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same period in the prior year, the business earned $4.28 earnings per share. The company’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.